(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of ...

Spatial analysis of protein or gene expression is vital to understanding the distribution, phenotypes, and interactions between cells within tumor microenvironment (TME). Traditionally, multiplexed ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, ...

56% of patients in the meta-analysis population were T3 with ≥12 nodes examined. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text ...

Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) This is an ASCO Meeting Abstract from the ...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever ...